Abstract. The purpose of this study was to evaluate the teratogenic potential of mefloquine (Lariam) in pregnancy, based on the Roche International Spontaneous Reporting System. Lariam is an anti-malarial drug used both in prophylaxis and treatment of malaria. Teratogenic effects were observed in animals but data from humans are lacking. Women of childbearing potential are currently advised to take contraceptive precautions up to three months after the last dose. The study included 1,627 spontaneous reports of women exposed to Lariam before or during pregnancy, which were received by Roche worldwide since introduction on the market. The data were analyzed considering pregnancy and fetal outcome and type of congenital malformations. The birth prevalence of congenital malformations in women exposed to Lariam is estimated to be 4% and is not different from the prevalence observed in the general population. In addition, the congenital malformations observed with Lariam exposure do not show any specific pattern. The data from our study suggest that the teratogenicity, which was observed in animals at high doses, cannot be applied to humans.
Half the world's population lives in malaria-endemic areas and about 20-30 million people, mainly Europeans and North Americans, either travel or stay in malarious areas. Morbidity and mortality from this disease is considerably high with approximately 200 million incident cases and two million deaths annually. 1, 2 In such an environment, prophylaxis and treatment of the disease are of prime public health importance.
Various antimalarial drugs have been used over the years. However, for most of these drugs, the information is lacking to perform risk-benefit analysis for different settings so that the risk of acquiring serious malaria can be balanced against the risk of harm from the drugs. 3, 4 Mefloquine (Lariam; F. Hoffmann-La Roche, Basel, Switzerland) was introduced in 1985 with a proven high degree of efficacy in prophylaxis and treatment of Plasmodium falciparum malaria in both nonimmune and resident populations. Development of resistance has been in general far slower than expected and is less when compared with other anti-malarial drugs. 5 Collective evidence indicates that it is well tolerated and the most common adverse events are similar to those seen with other quinine-related anti-malarial drugs. [5] [6] [7] [8] Mefloquine was demonstrated to be teratogenic in animal studies at 5-20 times the recommended dosage for humans. 5, 9 The observed anomalies were domed cranium, hydrocephalus in rats, and cleft palate and skeletal anomalies in mice. Currently, women of child-bearing potential are advised to take contraceptive precautions up to three months after the last dose. It is recommended for use in pregnancy only if the expected benefit justifies the potential risk for the fetus. Data on human exposure are limited since studies in early pregnancy cannot be initiated for ethical reasons. Limited surveys conducted in nonimmune and resident populations did not reveal any increase in the risk of teratogenicity (Harinasuta T and others, unpublished data). [10] [11] [12] [13] 
METHODS
Roche collects spontaneous reports of adverse events observed in association with the use of Roche products. They include women who are exposed to drugs before or during pregnancy and they are followed up to the end of the pregnancy. The Roche Drug Safety Database is currently the largest source available to study the teratogenic potential of Lariam. The cut-off date for data presented in this review is September 10, 1996. Data are collected spontaneously by different local Roche companies and entered into the global Roche Drug Safety database. Reports are usually initiated by inquiries regarding the safety of Lariam in pregnancy. Pregnancy reports are collected prospectively (the outcome of the pregnancy is unknown at the time of reporting and ascertained through prospective monitoring of the pregnancy). Some pregnancy reports are received retrospectively after the outcome of pregnancy is known.
The major epidemiologic weaknesses of the data are reporting bias, which is an inherent nature of spontaneous reporting systems, lack of a suitable comparative group, and poor data on other possible teratogenic risk factors. Thus, findings in this paper focus on Lariam exposure, pregnancy outcome, fetal outcome, and type of malformations.
The Statistical Package for Social Sciences (SPSS, Inc., Chicago, IL) was used for the analysis of the data.
RESULTS
Reporting characteristics. A total of 1,627 reports of exposure to Lariam during pregnancy were received by Roche Drug Safety from worldwide sources; 1,526 (94%) cases exposed to Lariam before and during pregnancy were reported prospectively. Nearly 31% of the cases were from France (497), followed by Germany (482), the United Kingdom (401), and the United States (110). Other reporting countries were Switzerland, Canada, and Italy ( Figure 1) .
The majority of the cases were reported by physicians or other health professionals. Only 2.4% were consumer reports. There was a steady increase in the number of reports over the years. This increase corresponded to the increase in the number of countries where Lariam is registered and to the number of people using this drug (Figure 2) .
Characteristics of prospective cases. There were considerable difficulties in the study of the possible effects on the offspring of maternal drug exposure during pregnancy. Pro- spective follow-up and ascertainment of pregnancy outcome in reports on accidental or necessary pregnancy exposures is still the best available method even though the size of the cohort may be limited.
Since introduction of Lariam, 1,526 pregnant women were reported prospectively. Their mean age was 29.3 years (confidence intervals ϭ 29.1-29.5 years). The minimum reported age was 18 years and the maximum was 46 years.
The majority (97.7%) of the women were exposed to Lariam within two months before and/or during the first trimester of pregnancy. Most (95.3%) of women used the drug for prophylactic purposes (Table 1) .
Pregnancy and fetal outcome in prospective cases. Six hundred forty-six (42%) prospective pregnancy cases resulted in delivery and 325 (21%) resulted in 79 spontaneous and 246 therapeutic abortions. The remaining 555 cases were either ongoing pregnancies or pregnancies lost to follow-up (Table 2) . A total of 32 congenital malformations were observed among the 1,526 prospectively followed-up pregnancies. Six hundred forty-six deliveries resulted in 26 congenital malformations, 33 other pregnancy-related and perinatal problems, and 587 normal babies. These results correspond to a birth prevalence of 4% (26 of 646) congenital malformations in this cohort.
No information was reported for the aborted fetuses in 236 of 246 induced abortions. Five abortions were performed after sonographic diagnosis of congenital malformation in a fetus and four abortions were induced due to other pregnancy-related or perinatal disorders. Information was available on only six fetuses of 79 spontaneous abortions. One had a chromosomal disorder and four had placental disorders and blighted ovum. All of the congenital malformations and 39 other pregnancy-related and perinatal problems were observed among prospectively monitored pregnancies in which exposure to Lariam was either before conception or during the first trimester of pregnancy (Table  3) .
Characteristics of malformations. To detect a potential specific pattern of malformations, it is valuable to look at all prospective and retrospective cases in which malformations were reported. In addition to 32 prospectively ascertained cases of malformations, 24 malformations were reported retrospectively (from 16 deliveries, seven abortions, and one pregnancy outcome not specified). The malformations did not represent a specific pattern (Table 4) . They were of different types and corresponded to the trend that would have been observed in the general population. The most frequent malformations were of the nervous system, musculoskeletal system, circulatory system, and chromosomal abnormalities.
Characteristics of other disorders. Ninety-four reports of other disorders were received in 41 prospective and 10 retrospective cases. They included intrauterine growth retardation, premature/low birthweight babies, placental disorders, and other neonatal problems such as jaundice, gastroesophageal reflux, dermatitis, thrombopenia, bradycardia, and sudden infant death (Table 5 ).
DISCUSSION
Birth defect monitoring programs are limited in their ability to detect new teratogens, mainly because of the small cohort size of the patients exposed. 14 Therefore, databases from drug companies are a major tool in assessing the teratogenic potential of a drug because the cohort size of the patients exposed to the drug is much higher.
Several criteria have to be met to demonstrate that a drug is teratogenic. 15 These are supportive evidence from fields other than epidemiology (e.g., pharmacology, toxicology), an increase in prevalence of congenital malformations among exposed women, a specific pattern of malformations, and timing of exposure.
Initial teratology studies were carried out in 1976 in rats and mice (Short RD and others, unpublished data). At doses Ն 100 mg/kg, Lariam produced soft tissue and skeletal anomalies. However, at doses of 10 or 20 mg/kg, the drug was not teratogenic. Data from a study in cynomolgus monkeys (F. Hoffmann-La Roche, unpublished data) suggested that treatment with a single Lariam dose of 20 mg/kg of body weight on gestation days 30 and 117 did not induce embryotoxicity or fetotoxicity, nor did it increase the incidence of abortions. In conclusion, animal studies demonstrated that Lariam was teratogenic at very high doses in rats and mice. A recent study 16 investigated the placental transfer of Lariam and concluded that the low concentration of mefloquine in the fetal circulation provides support for using mefloquine in pregnant women.
The second and most important criterion is that the prevalence of congenital malformations in exposed women is higher than in nonexposed women, resulting in a substantial relative risk associated with the exposure. The prevalence of congenital malformations should be calculated only from prospective cases, due to the reporting bias. Once the fetal outcome is known, congenital malformations are more likely to be reported than normal babies. Indeed, 24 congenital malformations were reported from 101 retrospective cases, whereas 32 congenital malformations were reported from 1,526 cases that were prospectively followed-up. In 192 prospective pregnancy cases, the pregnancy was still ongoing at the cut-off date and these cases are excluded from the prevalence calculation. In 363 prospective cases, the pregnancy outcome was unknown because the patient was lost to follow-up. These cases most probably resulted in normal babies since if the outcome involved were a congenital malformation, it would probably have been reported.
Twenty-six congenital malformations were detected from 646 deliveries, which results in a 4% birth prevalence of congenital malformations in our cohort. Congenital malformation is defined as a morphologic defect resulting from a structural or chromosomal abnormality. The birth prevalence of congenital malformations that was reported from birth registries and population studies varies between 0.8% and 6.5%. [17] [18] [19] These variations may be due to different ascertainment methods (definition of congenital malformation, length of follow-up) and/or may reflect different risks in the populations studied. Despite this variation, there is a consensus at the present time that the birth prevalence of major congenital malformation in the general population is about 2.5%. 15 Therefore, our data suggest that the observed birth prevalence of congenital malformations in women exposed to Lariam is not higher than the expected birth prevalence of congenital malformations in the general population.
The birth prevalence of congenital malformations represents the congenital malformations observed in liveborn and stillborn infants and is lower than the true incidence of congenital malformations, i.e., the proportion of embryos in which they are laid down. The birth prevalence is only the tip of the iceberg and could be substantially influenced by an increase in spontaneous abortions and/or therapeutic abortions.
Five abortions were induced after a sonographic diagnosis of a congenital malformation. Four abortions were induced due to other pregnancy-related or perinatal disorders. For the remaining 236 induced abortions, no reason for inducing abortion was specified. However, it can be reasonably assumed that the most likely reason was a concern for the outcome because of the recommendations in the product information on the use of Lariam in pregnancy. Therefore, the data do not suggest that the number of malformations in completed pregnancies is reduced due to prenatal detection of fetal damage. * CNS ϭ central nervous system; NOS ϭ not otherwise specified; ASD ϭ atrial septal defect; VSD ϭ ventricular septal defect; PDA ϭ patent ductus arteriosus. The prevalence of spontaneous abortions in our cohort is 8.1% (79 of 971) and is not different from that of the general population. 20 In only six cases was information on the fetus reported: one normal fetus, one case of a chromosomal disorder and four cases of placental disorders. These data also do not suggest any adverse impact on the course of the pregnancy and any increased risk of congenital malformations in uncompleted pregnancies.
A third criterion to be considered is the type of malformation. If the malformations observed with the exposure are of one or a few specific types, this is strong evidence to support a teratogenic effect of the exposure. To analyze this, we looked at all malformations reported prospectively and retrospectively with Lariam exposure (Table 4 ) and did not observe any specific pattern of malformations. The malformations reported were of various organ systems and there was no increase in specific defects.
A fourth criterion is that the increase in the specific type of malformations should correspond to the time of exposure in pregnancy at which the malformations would have originated. Since no increase in specific malformations was observed in our cohort, this criterion does not apply. Nevertheless, we analyzed fetal outcome according to exposure trimester ( Table 3) . Time of exposure was defined based on actual intake of the drug, realizing that the time of teratogenic risk could be different due to its long half-life. No significant differences in fetal outcome could be observed in relation to the trimester of Lariam exposure.
Finally, it is important to consider the power of our data. A sample size of 646 prospective deliveries as in our prospective cohort is able to detect a two-fold or greater increase in the risk of congenital malformation with 90% power at a 95% confidence interval, assuming a background incidence of 2.5%. The relative risk associated with mild teratogens has been estimated at 2-5, with strong teratogens such as isotretinoin at 20-25 and with potent teratogens such as thalidomide at 175. 14 The impact of malaria during pregnancy on mother and fetus has been well established and there is a great need for both prophylaxis and treatment of malaria in pregnant women. 21, 22 Prophylactic users constitute a bigger population at risk since 95% of Lariam users are travelers to malariaendemic areas. Data on treatment is limited, not only because the majority of the exposed population is prophylactic users, but because therapeutic use of the drug is mainly in countries where reporting and data collection systems are nearly nonexistent. Our study failed to demonstrate a teratogenic effect of prophylactic Lariam use in humans. Therefore, we conclude that Lariam can be used in pregnant women for prophylaxis of malaria.
